Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Atlanta, Georgia

This page shows live ClinicalTrials.gov search results for Atlanta, Georgia, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 12:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
13077
Shown on this page
12
Current sort
Recently updated
Location scope
Atlanta, GA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Atlanta, Georgia. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 661–672 of 13,077 matching trials in Atlanta, GA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Atlanta

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Lupus Erythematosus, Systemic
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
40
States / cities
Beverly Hills, California • Hemet, California • La Palma, California + 35 more
Conditions
Multiple Myeloma
Interventions
Teclistamab, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
Completed Not applicable Interventional

The PEERLESS II Study

NCT06055920
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
Conditions
Atrial Fibrillation
Interventions
Milvexian, Apixaban, Placebo, Apixaban Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
20,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
216
States / cities
Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
Conditions
Crohn Disease
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,092 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
64
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 51 more
Conditions
Angelman Syndrome
Interventions
GTX-102, Sham-LP
Drug · Procedure
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
4 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Conditions
Multiple Myeloma
Interventions
Cilta-cel
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more
Conditions
Angelman Syndrome
Interventions
GTX-102
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 3 more
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Conditions
Cutaneous Sarcoidosis
Interventions
Oral Brepocitinib, Oral Placebo
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Conditions
HIV -1 Infection
Interventions
Every 4-week long-acting injectable cabotegravir and rilpivirine
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
Conditions
Crohn's Disease
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
109
States / cities
Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more